.Pharmacolibrary.Drugs.ATC.C.C10AA03

Information

Pravastatin is an HMG-CoA reductase inhibitor (statin) used to lower cholesterol and triglycerides in the blood, primarily to prevent cardiovascular disease. It is approved and widely used for the treatment of hypercholesterolemia and to reduce the risk of heart attack and stroke.

Pharmacokinetics

Pharmacokinetic parameters observed in healthy adult volunteers after a single oral dose.

References

1. Stoll, F, et al., & Blank, A (2025). Effect of Staggered vs. Simultaneous Co-Administration of Bempedoic Acid on Pharmacokinetics of Pravastatin: Randomized, Cross-Over Clinical Trial in Healthy Volunteers. Pharmaceutics 17(1) –. DOI:10.3390/pharmaceutics17010060 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39861708

2. Escobar, Y, et al., & Hoyo-Vadillo, C (2005). Pharmacokinetic properties of pravastatin in Mexicans: An open-label study in healthy adult volunteers. Current therapeutic research, clinical and experimental 66(3) 238–246. DOI:10.1016/j.curtheres.2005.06.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24672127

3. Pincus, KJ, & Hynicka, LM (2013). Prophylaxis of thromboembolic events in patients with nephrotic syndrome. The Annals of pharmacotherapy 47(5) 725–734. DOI:10.1345/aph.1R530 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23613095

Revisions

• 06/2025 initial generated model